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Summary 
We previously demonstrated that a spontaneous Thl response against glutamate decarboxylase 
(GAD65) arises in NOD mice at four weeks in age and subsequently T cell autoimmunity 
spreads both intramolecularly and intermolecularly. Induction of passive tolerance to GAD65, 
through the inactivation of reactive T cells before the onset of autoimmunity, prevented deter- 
minant spreading and the development of insulin-dependent diabetes mellitus (IDDM). Here, 
we examined whether an alternative strategy, designed to induce active tolerance via the en- 
gagement of Th2 immune responses to GAD65, before the spontaneous onset of autoimmu- 
nity, could inhibit the cascade of Thl responses that lead to IDDM. We observed that a single 
intranasal dministration fGAD65 peptides to 2-3-wk-old NOD mice induced high levels of 
IgGl antibodies to GAD65. GAD65 peptide treated mice displayed greatly reduced IFN~/re- 
sponses and increased IL-5 responses to GAD65, confirming the diversion of the spontaneous 
GAD65 Thl response toward a Th2 phenotype. Consistent with the induction of an active 
tolerance mechanism, splenic CD4 + (but not CD8 +) T cells from GAD65 peptide-treated 
mice, inhibited the adoptive transfer of IDDM to NOD-scid/scid mice. This active mechanism 
not only inhibited the development ofproliferative T cell responses to GAD65, it also limited 
the expansion ofautoreactive T cell responses to other [3 cell antigens (i.e., determinant spread- 
ing). Finally, GAD65 peptide treatment reduced insulitis and long-term IDDM incidence. 
Collectively, these data suggest that the nasal administration f GAD65 peptides induces aTh2 
cell response that inhibits the spontaneous development ofautoreactive Thl responses and the 
progression of ~ cell autoimmunity in NOD mice. 
W e previously demonstrated in non-obese diabetic (NOD) 1 mice that autoreactive Thl cell responses 
develop spontaneously and gradually spread both intramo- 
lecularly and intermolecularly, creating a cascade of re- 
sponses that ultimately destroys the insulin-secreting ~ cells 
and results in insulin-dependent diabetes mellitus (IDDM) 
(1). Autoantigen based therapies offer the opportunity to 
prevent, or inhibit, this amplificatory cascade through 
mechanisms that are minimally invasive. There are two ba- 
sic autoantigen-based immunotherapeutic strategies. The 
first strategy, passive tolerance, aims to inactivate, or pre- 
1Abbreviations used in this paper: GAD, glutamate d carboxylase; hsp, heat 
shock protein; IDDM, insuhn-dependent iabetes mellitus; NOD, non- 
obese diabetic. 
vent the priming of autoreactive T cells by presenting anti- 
gen without appropriate costimulatory signals, or by inter- 
feting with the formation of MHC/TCR complexes through 
peptide antagonists or monoclonal antibodies (reviewed in 
references 2 and 3). Therapies based on passive tolerance 
are highly specific, but require detailed knowledge of the 
target antigens, the effector TCR or the peptide/MHC 
complex they recognize. Therefore, passive tolerance has 
almost exclusively been used to prevent experimentally in- 
duced autoimmune disease, in which the initiating autoan- 
tigen is defined. 
We demonstrated the efficacy of passive tolerance to 
prevent spontaneous ~3 cell autoimmunity in NOD mice 
by identifying GAD65 as the earliest known T cell target 
antigen and demonstrating that inactivation of GAD65- 
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reactive T cells (by the intravenous administration f GAD65), 
before the loss of  self-tolerance, prevented the development 
of  [3 cell autoimmunity (1). The GAD65 treated mice did 
not have detectable levels of  GAD65 autoantibodies and 
their splenic T cells failed to protect recipients in adoptive 
transfer experiments, consistent with the induction of pas- 
sive tolerance (J. Tian and D.L. Kaufman, unpublished ob- 
servations). 
The second immunotherapeutic strategy involves ad- 
ministering autoantigens in modes that induce protective 
immune responses, creating active forms of  self-tolerance 
(3-8). This approach does not require knowledge of  the 
initial target antigen and its protective ffect may not be 
confined only to the administered autoantigen, as the acti- 
vated immune responses may downregulate effector T cells 
through "bystander" suppression (4). A recently favored 
mechanism for active tolerance involves the induction of 
Th2 cells that protect a target issue via the local release of  
cytokines that downregulate Th l  cells (9-12). However, 
evidence demonstrating the protective ffects of  Th2 cells 
in autoimmune disease has been largely confined to experi- 
mentally induced diseases (4). In the case of  IDDM, Th2 
cells have in fact been suggested to be both nonprotective 
and nondiabetogenic in adoptive transfer experiments (13). 
We reasoned that i f  inactivation of  Th l  responses to 
GAD65 before the onset of  autoimmunity prevents [3 cell 
autoimmunity in NOD mice, the early priming of  a Th2 
response to GAD65 could also interfere with diabetogene- 
sis--either by diverting the pool of  GAD65-reactive pre- 
cursor T cells from developing toward a Th l  phenotype, 
or by downregulating effector T cells in the target organ 
via bystander suppression. It is not known however, what 
effect the induction of  Th2 responses to an autoantigen, 
before the spontaneous development of  pathogenic Th l  
responses to that autoantigen, would have on determinant 
spreading and disease progression. Moreover, it is unclear 
what modes of  antigen administration would induce Th2 
responses, whereas antigens are easily delivered to mucosal 
surfaces, this treatment has been recently reported to in- 
duce a variety of T cell responses (i.e., peripheral deletion, 
anergy, and activation o fCD4 + and CD8 + cells, references 
4, 6, 14-16). Here, we show in NOD mice, that a single 
nasal administration of  GAD65 peptides, before the onset 
of  autoimmunity, induces a Th2 cell response that actively 
diverts/downregulates the development ofautoreactive Th l  
responses and inhibits autoimmune disease progression. 
Materials and Methods 
Mice. NOD mice (Taconic Farms Inc., Germantown, NY) 
were bred under SPF conditions. Only female NOD mice were 
used in this study. Insulitis begins at 4 wk and the average age of 
disease onset in females is at 22 wk. Approximately 80% of the fe- 
male mice display IDDM by 30 wk in age. IDDM increases to 
,'-,90% by 40 wk in age and remains table thereafter. 
Antiget,s. We previously characterized in NOD mice the de- 
velopment of T cell autoreactivity o a panel of overlapping 
GAD65 peptides that span the molecule (1). We administered a 
mixture of the synthetic peptides that contain the earliest GAD65 
T cell target determinants (peptides 17, 34, 35, and 36, references 
1 and 17), or a control GAD65 peptide that does not contain a T 
cell target determinant (peptide 11 in references 1 and 17). These 
peptides, as well as the hsp65 immunodominant peptide (18) 
were prepared as previously described (17). To avoid confusion 
between the experimental GAD65 peptides (peptides 17, 34, 35, 
36) that contain T cell determinants and the control GAD65 pep- 
tide (peptide 11) which does not, we refer to peptide 1l as the 
"control" peptide. Mouse GAD65 (19) and control Escherichia coli 
J3-galactosidase, used in T cell proliferation assays, were purified 
as previously described (I). Human GAD65, used in ELISA assays 
for autoantibodies, was provided by Synectics Biotechnology 
(Stockholm, Sweden). Bovine insulin B chain was from Sigma 
Chemical Co. (St. Louis, MO). Hen egg white lysozyme peptide 
(HELiI_2s), which contains a dominant determinant, was pro- 
vided by Eli Sercarz. 
Treatment. Female NOD mice at 2-3 wk were given a single 
intranasal dose of a mixture of four GAD65 peptides (peptides 17, 
34, 35, 36, 50/,g of each in 50/*1 PBS). Control NOD mice re- 
ceived a single dose of the control peptide (200/,g in 50 I*l PBS). 
Mice received peptides while under light ether anesthesia using a 
thin drawn-out plastic tube (inserted 5-10 mm intranasally) at- 
tached to a Hamilton syringe. At 12 wk, some mice were killed 
to characterize splenic T cell responses and insulitis. The remain- 
ing mice were followed up to 1 yr to determine the effect of 
treatment on long-term IDDM frequency. Urine glucose levels 
were monitored weekly for diabetes by Tes-tape. After observing 
abnormal glucose in the urine, blood glucose levels were moni- 
tored twice weekly. Two consecutive blood glucose levels >13 
Ltmol/L were considered as IDDM onset. 
GAD65 Autoantibody Assays. GAD65 (10/*g/ml) was bound 
to 96-well plates (Nunc) in 0.1 M NaHCO 3, pH 8.5, at 4~ 
overnight. The wells were rinsed with PBS and then blocked 
with 3% BSA in PBS for 1 h. Mouse sera was added (0.1 nil of a 
1/500 dilution) and incubated 1 h at 37~ Following washing, 
bound Ig was characterized using altlnity-purified HRP-coupled 
goat anti-mouse IgG+A+M (H+L) (Pierce Chem.), or HRP- 
coupled goat anti-mouse isotype-specific antibodies for IgG 1, IgGaa, 
lgM (Southern Biotech Associates) and 2,2'-azino-bis(3-ethylbenz- 
thiazoline-6-sulfonic acid) (Sigma Chemical Co.). Sera from un- 
treated BALB/c and AKR mice were used as negative controls. 
Cytokine Assays. Spleen cells were plated at 8 • 10 ~ cells/ml 
in 24-well microtiter plates as previously described (1). GAD65 
or [3-galactosidase w re present at 100/.tg/ml. After 48 h, culture 
supernatants were analyzed by lymphokine-specific ELISA. For 
the IFN"/ELISA, mAb R4-6A2 was used as the capturing agent 
and XMG 1.2-biotin (PharMingen, San Diego, CA) was used in 
conjunction with SAV-AP and PNPP for the detection of bound 
lymphokine. For IL-5 detection, mAb TR.FK5 and TP, YK4- 
biotin (PharMingen) were used. The concentration of lympho- 
kines was determined by comparison with a standard curve of re- 
combinant murine IFN~/or IL-5 (PharMingen). 
Adoptive Transfer of Diabetes. Ten million splenic mononuclear 
cells from untreated-diabetic mice were mixed with an equal 
number of splenic mononuclear cells from (18-20 wk old) exper- 
imental or control peptide treated mice, and the mixture injected 
i.v. into 10-wk-old NOD-scid/scid mice (20). A positive control 
group received 1 • 107 splenic mononuclear cells obtained from 
only untreated diabetic mice. 
To examine the T cell subset hat conferred protection from 
the adoptive transfer of disease, CD4 + and CD8 + splenic T cell 
populations were isolated from 5-wk-old control and GAD65 
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peptide-treated mice (3 wk after treatment) using T cell and 
CD4 + and CD8 + enrichment columns (R&D Systems, Minne- 
apolis, MN). Three-color FACS | analysis using PE-anti-CD3, 
Cy-chrome-anti-CD4 +, and FITC-anti-CD8 + antibodies (Phar- 
Mingen) showed that the negatively selected CD4 + subset con- 
tained less than 1% CD8 + T cells, and that the CD8 § subset con- 
tained less than 3% CD4 + T cells. 5 • 106 purified T cell subsets 
from control or GAD65 peptide treated mice were mixed with 
107 splenic mononuclear cells from diabetic NOD mice and in- 
jected i.v. into NOD-scid/scid mice. 
T Cell Proliferation Assays. At 12 wk of age the mice were 
killed and their spleen cells were tested directly in vitro for prolif- 
erative responses to GAD65, heat shock protein (hsp65), 13-galac- 
tosidase and the insulin B chain, as previously described (1). 
Histopathology. At 12 wk of age, pancreata from control and 
experimental NOD mice (at least five from each group) were ex- 
amined for insulitis as described previously (1). The severity of 
mononuclear cell infiltration was defined histologically (0 = no 
lymphocytic infiltration; 1 = <25%; 2 = 25-50%; 3 = 50--75%; 
4 = >75%, reference 21). 
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Figure 1. The nasal administration of GAD65 determinants induces 
GAD65-specific autoantibodies of the IgG 1 isotype. Female NOD mice 
at 2-3 wk were given a single intranasal dose of a control peptide, or 
GAD65 peptides that contain early T cell target determinants. At 12 wk, 
sera from control (&) and GAD65 peptide (O) treated mice were tested 
for anti-GAD65 antibodies. The isotype of the GAD65 antibodies was 
characterized using an ELISA assay and isotype-specific antibodies as de- 
scribed in Materials and Methods. Unmanipulated NOD mice and con- 
trol peptide-treated mice had low levels of GAD65 autoantibodies, that 
were only slightly greater than the background levels we observed in sera 
from BALB/c and ~ mice (data not shown). There was a linear rela- 
tionship between the OD and the titer of the antibody (data not shown). 
The data are represented as the mean absorbance values of samples from 
individual mice. The background OD ranged from 0.05-0.07 in two sep- 
arate experiments. 
sal dose o f  peptides at 2 -3  wk and humoral  responses to 
GAD65 were tested at 12 wk, We observed that NOD 
mice treated with the control  peptide had low levels o f  
GAD65 autoantibodies (Fig. 1), similar to that observed in 
unmanipulated age-matched NOD mice, and only slightly 
greater than that found in BALB/c and AKR mice (data 
not  shown). However ,  high levels o f  GAD65 autoantibod- 
ies were observed in most o f  the GAD65 pept ide-treated 
NOD mice, indicating that the treatment riggered a T 
ce l l -dependent  ant i -GAD65 B cell response. To  identify 
the type o f  T cell that provided help for GAD65 autoanti-  
body product ion,  we characterized the isotype o f  the anti- 
GAD65 immunoglobins.  The GAD65 autoantibodies in 
the GAD65 pept ide-treated group were almost exclusively 
o f  the IgGl subclass (Fig. 1), wh ich  is indicative o f  Th2 
help (22, 23). In contrast, IgGaa GAD65 autoantibodies, 
which require Th l  help, were at very low levels in both 
the experimental  and control  groups. These data suggest 
that nasal administration o f  GAD65 peptides activates a 
GAD65-speci f ic  Th2 response. 
T Cells from GAD65 Peptide Treated Mice Display Decreased 
IFN y and Increased IL-5 Production in Response to GAD65. 
We previously demonstrated that unmanipulated NOD 
mice at 12 wk  have a clonally expanded, CD4 + L-selectin-,  
IFN~/secret ing populat ion o f  GAD65-speci f ic  T cells, (i.e., 
a Th l  response to GAD65,  reference 1). Consistent wi th 
our previous findings, we observed that T cells f rom 12 wk  
old control peptide-treated NOD mice secreted high levels 
o f  IFN'y in response to GAD65 challenge in vitro (Fig. 2). 
In contrast, T cells f rom GAD65 pept ide-treated NOD 
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Figure 2. T cells from GAD65 peptide-treated mice display decreased 
IFN~/ and increased IL-5 production in response to GAD65. Splenic T 
cells from 12-wk-old NOD mice that had received a single nasal adminis- 
tration at 2-3 wk of experimental (open bar) or control GAD65 peptides 
(black bar) were tested for their pattern of cytokine responses to GAD65. 
The IFN3~ responses in the control group were similar to that found in 
the unmanipulated NOD mice of our previous tudy (1). IFN~ or IL-5 
were not detected in cultures with control 13-galactosidase or medium 
alone (data not shown). Values shown are mean -+ SEM of triplicate as- 
says in two separate experiments. 
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Figure 3. Adoptive cotransfer 
of CD4 + splenic T cells from 
GAD65 pepdde-treated mice 
protects recipient NOD-scid/scid 
mice from IDDM. (a) At 18-20 
wk, splenic mononuclear cells 
from mice treated with control 
(A) or GAD65 (O) peptides 
were cotransferred with T cells 
from diabetic NOD mice to 
NOD-scid/sdd mice. A positive 
control group received cells only 
from untreated iabetic NOD 
mice (O) (n = 10 for all groups). 
(b) Unfractionated splenic T cells 
(A), CD4 + (I) and CD8 + (V) 
T cells from control peptide- 
treated mice, or unfractionated 
splenic T cells ((3), CD4 + ([]) 
and CD8 + (A) T cells from 
GAD65 peptide-treated mice, 
were mixed with mononuclear 
cells from unmanipulated dia- 
betic NOD mice and cotrans- 
ferred into NOD-scid/scid mice. 
Positive control, unfractionated 
T cells from only untreated ia- 
betic mice (<)). (n = 8-10 for all 
groups). 
more, while IL-5 secretion was almost undetectable in the 
control group, clear IL-5 responses were detectable in 
some mice of  the experimental group, conf irming the acti- 
vation of Th2 responses. 
Adoptive Cotransfer of Splenic T Cells from GAD65 Pep- 
tide-treated Mice Protects Recipient NOD-scid/scid Mice from 
IDDM. We next examined whether T cells from GAD65 
peptide-treated NOD mice could actively inhibit  the 
adoptive transfer of  diabetes. Splenic mononuclear cells from 
mice treated with GAD65 or control peptides were cotrans- 
ferred with T cells from diabetic NOD mice to NOD-scid/ 
scid mice. All of  the positive control mice that received cells 
from unmanipulated diabetic NOD mice, and 90% of  the 
mice that received a mixture of  cells from unmanipnlated 
diabetic and control peptide-treated NOD mice, became 
diabetic with in 5 wk  after transfer (Fig. 3 a). In contrast, 
only 20% (n = 10) of the NOD-scid/scid mice that received 
a mixture of  cells from GAD65 determinant treated mice and 
unmanipulated diabetic mice developed IDDM (P <0.01).  
Those recipients that did develop IDDM showed a delayed 
onset of  disease relative to the control groups. 
To examine the T cell subset hat inhibited disease de- 
velopment,  splenic CD4 + and CD8 + T cell populations 
were isolated from the spleens of  control or GAD65 pep- 
t ide-treated mice and cotransferred with mononuclear  cells 
from diabetic NOD mice into NOD-sdd/sdd mice. Mice 
that received CD4 + or CD8 + T cells from control pep- 
t ide-treated mice progressed to IDDM with in 4 wk  (Fig. 3 
b). In contrast, the CD4 +, but  not  the CD8 +, T cell popu-  
lation of  the GAD65 peptide-treated mice conferred pro-  
tection from the adoptive transfer o f  disease, at a level sim- 
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Figure 4. The nasal administration fGAD65 peptides inhibits deter- 
minant spreading ofT cell autoimmunity. Splenic T cells from 12-wk-old 
control (A) or GAD65 peptide-treated ((3) mice were tested for prolifer- 
ative responses to GAD65, the immunodominant hsp65 peptide and the 
insulin B chain. Background for medium alone ranged from 1,200-2,500 
cpm. Positive control Con A (1 Ixg/ml)-stimulated T cell proliferation 
ranged from 38,000-43,000 cpm. The dashed line indicates the level con- 
sidered to be a significant response (threefold above the mean background 
level). Mice from both groups were tested simultaneously in two separate 
experiments. None of the antigens induced proliferation of splenic T cells 
from BALB/c mice (data not shown). 
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Figure 5. The nasal administration of GAD65 peptides inhibits IDDM. 
Female NOD mice at 2-3 wk were given a single intranasal dose of con- 
trol (&) or GAD65 peptides (O) and were followed up to 52 wk to deter- 
mine the effect of treatment onlong-term IDDM incidence as described 
in Materials and Methods. (n = 15 for each group). 
data demonstrate hat the nasal administration of GAD65 
peptides can induce potent CD4 + regulatory cells that sup- 
press the adoptive transfer of IDDM. 
The Nasal Administration f GAD65 Peptides Inhibits Spread- 
ing ofT Cell Autoimmunity. Splenic T cells from 12-wk- 
old experimental nd control mice were tested for their 
proliferative responses to 13 cell autoantigens. T cells from 
control mice displayed strong proliferative responses to 
GAD65 and hsp65 and some of the mice displayed T cell 
responses to insulin B chain (Fig. 4). The levels of these 
proliferative responses were similar to those we observed in 
untreated NOD mice (1). In contrast, nearly all of the 
NOD mice treated with peptides containing GAD65 target 
determinants failed to display significant proliferative re- 
sponses to GAD65 (Fig. 4). Furthermore, none of the mice 
in the experimental group displayed significant proliferative 
responses to hsp65 or the B chain of insulin. Thus, the nasal 
administration of GAD65 determinants inhibited the inter- 
molecular spreading of the autoreactive Thl  responses that 
naturally occur in NOD mice. 
The Nasal Administration fKey GAD65 Peptides Reduces 
Insulitis and IDDM Incidence. Examination of the pancre- 
ata from 12-wk-old control mice revealed that all islets had 
infiltrating lymphocytes at levels essentially identical to 
those we observed in unmanipulated NOD mice (1). In 
contrast, several of the pancreata from the GAD65 pep- 
tide--treated group were virtually free of insulitis. The 
overall insulitis score for pancreata from mice in the exper- 
imental group (0.9 + 0.4) was less than half that ofpancre- 
ata from the control group (1.9 + 0.7). 
We next examined the effect of GAD65 peptide admin- 
istration on the long-term frequency of IDDM in NOD 
mice. 90% of the mice receiving the control peptide were 
diabetic by 35 wk (Fig. 5), matching the time course of 
IDDM incidence observed in unmanipulated female NOD 
mice. In contrast, 60% of the GAD65 peptide--treated mice 
remained isease free at 52 wk (P <0.03), and those that 
did become diabetic displayed a delayed onset of disease. 
Thus, the single nasal administration of GAD65 determi- 
nants early in life significantly delayed, or prevented, IDDM 
onset. 
Interestingly, high levels of anti-GAD65 IgG 1 autoanti- 
bodies were detected in the sera of all 52-wk-old GAD65 
peptide treated mice that had remained isease free. How-  
ever, GAD65 autoantibody levels greatly dechned just be- 
fore disease onset in the GAD65-treated mice which devel- 
oped IDDM (data not shown). 
Discuss ion  
The NOD mouse has been suggested to be deficient in 
Th2 development (24) and the spontaneous autoimmune 
response to 13 cell antigens in NOD mice appears to be 
highly Thl  biased (1), factors which may predispose these 
mice to IDDM susceptibility. We hypothesized that if Th2 
responses could be induced to 13 cell autoantigens at an 
early age, it might inhibit the development of pathogenic 
Thl  responses and autoimmune disease progression. As 
GAD65 is a key initial target antigen in NOD mice, we 
examined whether it is possible to administer GAD65 in a 
mode that would induce GAD65-specific Th2 responses 
and shift the development ofa Thl  biased anti-GAD65 re- 
sponse in NOD mice. 
We observed that a single intranasal administration of 
GAD65 peptides induced high levels of IgG1 anti-GAD65 
antibodies and greatly reduced IFN~/while increasing IL-5 
responses to GAD65, apparently shifting the normal Th l /  
Th2 balance toward a Th2 response. Consistent with the 
induction of an active tolerance mechanism, splenic T cells 
from GAD65 peptide-treated mice inhibited the adoptive 
transfer of disease to NOD-sdd/scid mice. This protection 
was conferred by the CD4 +, and not the CD8 +, T cell 
subset. This active mechanism inhibited the development 
of proliferative T cell responses to GAD65 as well as other 
13 cell antigens and reduced insuhtis and long-term IDDM 
incidence. While GAD65 autoantibodies remained high in 
the GAD65 peptide-treated mice that did not develop dis- 
ease, GAD65 autoantibody levels greatly declined in the 
GAD65-treated mice which developed IDDM, consistent 
with Th2 regulation of IDDM development. Collectively, 
these data suggest hat the nasal administration of GAD65 
peptides interferes with the development of the diabeto- 
genic process through the induction ofa Th2 response (ac- 
tive tolerance), rather than the clonal inactivation of 
GAD65-reactive cells (passive tolerance). 
The mechanism by which the induction of Th2 re- 
sponses interferes with disease progression may involve 
one, or several, of the following: (a) the induction of Th2 
responses before the spontaneous priming of Thl  responses 
may have driven a limited number of uncommitted, or not 
fully differentiated, Th0 cells toward a Th2 lineage; (b) the 
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first generation of  Th2 cells may have migrated to the tar- 
get organ where their local secretion ofcytokines may have 
downregulated antigen presentation i  the islets (25, 26), 
thereby limiting the amplificatory cascade of Thl  re- 
sponses; (c) alternatively, the local release of  cytokines by 
Th2 cells may have upregulated islet antigen presentation, 
which in the absence of appropriate costimulatory factors, 
caused the antigen-specific T cells that engaged these de- 
terrninants to be anergized or deleted (27), or; (d) the up- 
regulation of  islet antigen presentation may have caused T 
cell priming that was Th2 biased due to the IL-4 environ- 
ment that was established by the first wave of Th2 cells, 
creating an amplificatory cascade of Th2 responses; (e) The 
GAD-specific Th2 response may have locally downregu- 
lated Thl  cells through the secretion of  cytokines such 
as IL-10 and IL-4 (bystander suppression, references 4, 10, 
11, 22). 
Th2 cells are generally thought o exert protective func- 
tions in experimental models of  autoimmune disease (3, 4, 
9, 15) and administration of  IL-4 and IL-10 are anti- 
inflammatory (24, 28). However, two recent reports ques- 
tion whether Th2 cells exert anti-inflammatory functions. 
Katz et al. showed that Th2 cells fail to mitigate [3 cell de- 
struction when coinjected with Thl  cells in adoptive trans- 
fer experiments (13). Our conflicting findings may be due 
to differences in the nature and frequency of the autoanti- 
gen-reactive T cells used in our experiments. Katz et al. si- 
multaneously injected clonal populations of  preactivated 13 
cell-specific Thl  and Th2 cells. Under these conditions it 
is likely that Th2 cell secreted cytokines could not exert 
regulatory functions before Thl  cells engaged target deter- 
minants. We injected a mixed population of  unactivated 
spleen cells, in which the frequency of GAD65-reactive T 
cells was ,--,1 in 104-105 . Our  protocol may not have 
flooded the target organ with an autoreactive Thl  compo- 
nent, thus providing an opportunity for Th2 cells to exert 
protective functions. These experiments also targeted if- 
ferent 13 cell antigens, whereas our protocol induced GAD65- 
specific Th2 cells, the T cell populations used by Katz et al. 
have an unknown specificity. 
Apparently also contradicting the protective Th2 cell hy- 
pothesis, is the finding that IDDM is accelerated in trans- 
genic mice expressing IL-10 in their 13 cells (29). However, 
IL-10 may have complex functions. For example, IL-10 is 
a growth factor for CTL and facilitates their priming (30, 
31). Since CD8 + cells are involved in the pathogenesis of  
IDDM in NOD mice (32, 33), the IL-10 produced in the 
transgenic islets may have promoted an anti-J3 cell CD8 + 
response and accelerated disease progression. It is also possi- 
ble that other cytokines uch as IL-4 and IL-13 mediate the 
anti-inflammatory functions of Th2 cells. Thus, these two 
reports do not disprove a protective role for Th2 cells. To 
the contrary, our data substantiate he contention that Th2 
cells can serve a protective role. 
In conclusion, we have shown that a single nasal admin- 
istration of  peptides containing T cell target determinants 
can induce antigen-specific Th2 responses and inhibit the 
spontaneous cascade of events that lead to IDDM. Thus the 
inhalation of  autoantigen peptides may provide an easily 
administered, minimally invasive, immunotherapy to pre- 
vent spontaneous autoimmune disease. 
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